Holen Sie sich die Stockscreener-App
168.52
1.40%
-2.40
Handel nachbörslich:
169.00
0.48
+0.28%
Schlusskurs vom Vortag:
$170.92
Offen:
$170.94
24-Stunden-Volumen:
1.52M
Relative Volume:
0.56
Marktkapitalisierung:
$22.61B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$-433.19M
KGV:
-49.56
EPS:
-3.4004
Netto-Cashflow:
$-225.09M
1W Leistung:
+0.38%
1M Leistung:
+15.85%
6M Leistung:
+79.47%
1J Leistung:
+165.39%
1-Tages-Spanne:
$168.19
$173.10
1-Wochen-Bereich:
$161.22
$173.17
52-Wochen-Spanne:
$53.40
$176.58
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
168.52 | 22.53B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health (NASDAQ: GH) insider plans more sales after June disposals - Stock Titan
Ninepoint Partners LP Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Gains as Investors Continue to Weigh Strong Q2 Growth and Shield Momentum - Quiver Quantitative
B of A Securities maintains Buy on Guardant Health, raises target to $190 - scanx.trade
Lisanti Capital Growth LLC Takes $1.59 Million Position in Guardant Health, Inc. $GH - MarketBeat
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH - MarketBeat
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH - MarketBeat
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance - simplywall.st
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC - MarketBeat
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock - MarketBeat
How Guardant aims to expand cancer screening with a blood test - MedTech Dive
Guardant Health (NASDAQ: GH) insider plans August sale of 116 shares - Stock Titan
Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum - Yahoo Finance
GSA Capital Partners LLP Makes New $1.77 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: A 23.59% Upside Potential In Precision Oncology - DirectorsTalk Interviews
Informed Momentum Co LLC's Guardant Health Inc(GH) Holding History - GuruFocus
SWS Partners Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health(GH.US) Officer Sells US$7.65 Million in Common Stock - Moomoo
T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A - Stock Titan
Guardant Health Insider Sold Shares Worth $7,645,218, According to a Recent SEC Filing - marketscreener.com
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate - MarketBeat
Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells $7,645,056.00 in Stock - MarketBeat
Guardant Health CPO Monroe sells $7.6 million in stock By Investing.com - Investing.com South Africa
Guardant Health CPO Monroe sells $7.6 million in stock - Investing.com
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $65.06 vs Price $159.54 - GuruFocus
Guardant Health, Inc. $GH Position Increased by Quantinno Capital Management LP - MarketBeat
Guardant Health, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Guardant Health at canaccord growth conference: shield drives growth By Investing.com - Investing.com Canada
GH: Record growth in oncology and screening, with Shield adoption and payer coverage accelerating - TradingView
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million - Yahoo Finance
Guardant Health (GH) Just Gave Investors Something To Think About - Yahoo Finance
Handelsbanken Fonder AB Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health CCO Chris Freeman sells $10.7m in common stock - Investing.com
Chris Freeman Sells 63,605 Shares of Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guardant Health sees strong growth from MRD and screening, boosted by FDA approvals and guideline inclusion. - Pluang
Guardant Health: Screening And MRD Are Just Getting Started (NASDAQ:GH) - Seeking Alpha
Guardant Health grants 46,044 RSUs to 149 new employees under inducement plan - Bitget
Guardant Health (GH) holder plans 63,605-share stock resale - Stock Titan
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
How Guardant Health Inc. (GH) Affects Rotational Strategy Timing - Stock Traders Daily
Guardant Health, Inc. (GH) Stock Analysis: Assessing Growth Potential with a 15.32% Upside - DirectorsTalk Interviews
Empowered Funds LLC Trims Stock Position in Guardant Health, Inc. $GH - MarketBeat
Amundi Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Dimensional Fund Advisors LP Sells 123,826 Shares of Guardant Health, Inc. $GH - marketbeat.com
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
A Look at Guardant Health Inc (GH) After 6.9% Gain -- GF Value $64.74 vs Price $168.48 - GuruFocus
Guardant Health (GH) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 1,700 Shares of Stock - MarketBeat
Guardant Health director Manuel Hidalgo Medina sells $279k in stock - Investing.com
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $64.71 vs Price $157.58 - GuruFocus
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Director Hidalgo Medina Manuel - Moomoo
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):